(Q42553403)

2 November 2017

0 references

Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy (English)

1 reference

acute kidney tubular necrosis

2 November 2017

interstitial nephritis

1 reference

based on heuristic

inferred from title

1 reference

3

Isabelle Brocheriou

0 references

author name string

Judith Michels

1

1 reference

2 November 2017

Jean Philippe Spano

2

1 reference

2 November 2017

Isabelle Brocheriou

3

1 reference

2 November 2017

Gilbert Deray

4

1 reference

2 November 2017

David Khayat

5

1 reference

2 November 2017

Hassane Izzedine

6

1 reference

2 November 2017

14 March 2009

1 reference

2 November 2017

Case reports in oncology

1 reference

2 November 2017

2

1 reference

2 November 2017

1

1 reference

2 November 2017

53-56

1 reference

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma

2 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

FDA drug approval summaries: pemetrexed (Alimta).

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

Thymidine Rescue: An Antidote for Pemetrexed-Related Toxicity in the Setting of Acute Renal Failure

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2918829

Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20740145

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1159/000208377

1 reference

2 November 2017

1 reference

2 November 2017

1 reference